Can autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease?

Orbit

Volumn 28, Issue 4, 2009, Pages 256-261

  Gopinath, Bamini ^a   Wescombe, Leon ^a   Nguyen, Bao ^a   Wall, Jack R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Calsequestrin; Graves disease; Micro arrays; Ophthalmopathy; T lymphocytes; Thyroiditis; Upper eyelid retraction

Indexed keywords

CALSEQUESTRIN; RNA; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DNA MICROARRAY; ENDOCRINE OPHTHALMOPATHY; EYE INFLAMMATION; EYELID DISEASE; EYELID MUSCLE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; T LYMPHOCYTE; UPPER EYELID;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNITY; CALSEQUESTRIN; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GRAVES OPHTHALMOPATHY; HASHIMOTO DISEASE; HUMANS; INFLAMMATION; LYMPHOCYTES; MALE; MIDDLE AGED; OCULOMOTOR MUSCLES;

EID: 70350669885     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676830903104629     Document Type: Article

References (23)

1. Bahn RS. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88:1939-1946.
2. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, HeufelDer AE. Thyrotropin receptor expression in Graves' orbital adipose/ connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1998;83:998-1002.
3. Beard NA, Laver DR, Dulhunty AF. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Biophys Mol Biol. 2004;85:33-69.
4. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747-793.
5. De Bellis A, Sansone D, Coronella C, et al. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2005;62:24-29.
6. Diehn J, Diehn M, Marmor MR, et al. Differential gene expression in anatomical compartments of the human eye. Genome Biol. 2005;6:R74-20.
7. Fliegel L, Burns K, Wlasichu K, Michalak M. Peripheral membrane proteins of sarcoplasmic and endoplasmic reticulum. Comparison of carboxyl-terminal amino acid sequences. Biochem Cell Biol. 1989;67:696-702.
8. Forster G, Otto E, Hansen C, Ochs K, Kahaly G. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol. 1998; 112:427-434.
9. Gopinath B, Adam CL, Musselman R, Tani J, Wall JR. Antibodies against calsequestrin and type XIII collagen are good markers for chronic upper eyelid retraction. Ocul Immunol Inflamm. 2007;15:81-88.
10. Gopinath B, Musselman R, Adams CL, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy - correlation with clinical features. Thyroid. 2006b;16: 967-974.
11. Gopinath B, Musselman R., Beard N, et al. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease. Clin Exp Immunol. 2006a;145:56-62.
12. Gopinath B, Tani J, Bao N, Wall JR. Eye muscle and collagen XIII antibodies and eye signs in patients with transient and chronic thyroiditis. Thyroid. (in press).
13. Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi, T. Type XIII collagen is iDentified as a plasma membrane protein. J Biol Chem. 1998;273:15590-15597.
14. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Van Der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73:639-644.
15. Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg. 1993;9: 77-82.
16. Pappa A, Lawson JM, CalDer V, Fells P, Lightman S. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol. 2000 May;84(5):517-522.
17. Park H, Jeung A, Park IY, et al. Comparing skeletal and cardiac calsequestrin structures and their calcium binding: a proposed mechanism for coupled calcium binding and protein polymerization. J Biol Chem. 2004;279:18026-18033.
18. Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is Defined by a fundamentally distinct gene expression profile. PNAS (USA). 2001; 98:12062-12067.
19. Slupsky JR, Ohnishi M, Carpenter MR, Reithmeier RA. Characteristics of cardiac calsequestrin. Biochemistry. 1987;26:6539-6544.
20. Tani J, Wall JR. Analysis - Can the Development of thyroidassociated ophthalmopathy be explained by autoimmunity against eye muscle antigens? CMAJ. 2006;17:239-241.
21. Weetman AP. Graves' disease. N Engl J Med. 2000;343: 1236-1248.
22. Weetman AP, Cohen S, Gatter KC, Fells P, Shine B. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol. 1989;75: 222-227.
23. Yamada M, Li AW, Wall JR. Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management. Crit Rev Clin Lab Sci. 2000;37:523-549.